Rumery Kyle, Yunus Fahd, Frishman William H
From the Department of Medicine, Brown University/Rhode Island Hospital, Providence, RI.
Department of Medicine, Stanford University, Stanford, CA.
Cardiol Rev. 2020 Sep/Oct;28(5):256-261. doi: 10.1097/CRD.0000000000000301.
Myocardial depression is a common yet reversible phenomenon that occurs in patients in septic shock. Initially, it was unclear whether this provided an adaptive survival benefit, as early studies showed decreased mortality in septic patients with myocardial depression. However, subsequent larger studies have debunked this myth. Given that no benefit exists, cardiac dysfunction in septic patients may be monitored via echocardiography and may be treated with inotropic agents. Beta-blockers provide a novel avenue of treatment as they aid in reducing adrenergic overstimulation and cytokine production, which may drive the pathogenesis of septic shock. This review chronicles how the understanding of myocardial depression in sepsis has evolved and how it should be clinically managed.
心肌抑制是脓毒性休克患者中常见但可逆的现象。最初,尚不清楚这是否提供适应性生存益处,因为早期研究表明心肌抑制的脓毒症患者死亡率降低。然而,随后的大型研究揭穿了这一谬论。鉴于不存在益处,脓毒症患者的心脏功能障碍可通过超声心动图监测,并可用强心剂治疗。β受体阻滞剂提供了一种新的治疗途径,因为它们有助于减少肾上腺素能过度刺激和细胞因子产生,而这可能推动脓毒性休克的发病机制。这篇综述记录了对脓毒症中心肌抑制的认识是如何演变的,以及应如何进行临床管理。